Article
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
British journal of cancer - 13 Apr 2010
Handolias D, Hamilton A L, Salemi R, Tan A, Moodie K, Kerr L, Dobrovic A, McArthur G A
Abstract excerpt
BACKGROUND: Mutations in KIT are more frequent in specific melanoma subtypes, and response to KIT inhibition is likely to depend on the identified mutation. METHODS: A total of 32 patients with metastatic acral or mucosal melanoma were screened for mutations in KIT exons 11, 13 and 17. RESULTS: KIT mutations were found in 38% of mucosal and in 6% of acral melanomas. Three patients were treated with imatinib and...
Topics
- Adult
- Aged
- Antineoplastic Agents
- Benzamides
- Benzenesulfonates
- Female
- Humans
- Imatinib Mesylate
- Melanoma
- Middle Aged
- Mutation
- Neoplasm Metastasis